{"id":3198,"date":"2022-01-01T12:02:09","date_gmt":"2022-01-01T11:02:09","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=3198"},"modified":"2022-04-04T13:53:23","modified_gmt":"2022-04-04T11:53:23","slug":"zum-demenz-risiko-unter-hormonersatz-therapie-besser-postmenopausale-hormon-therapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2022\/zum-demenz-risiko-unter-hormonersatz-therapie-besser-postmenopausale-hormon-therapie","title":{"rendered":"Zum Demenz-Risiko unter Hormonersatz-Therapie (besser: postmenopausale Hormontherapie) [CME]"},"content":{"rendered":"<p>Etwa 80% der Frauen im Klimakterium beschreiben \u2013 in sehr unterschiedlicher Auspr\u00e4gung \u2013 Symptome wie Hitzewellen, Schlafst\u00f6rungen, Depression und kognitive Defizite. Neben bekannten Risiken im Zusammenhang mit einer Hormonersatz-Therapie (\u201ehormone replacement therapy\u201c = HRT; vgl.\u00a0) gibt es widerspr\u00fcchliche Untersuchungsergebnisse zur Entwicklung einer Demenz unter HRT \u00a0. Die Women\u2019s Health Initiative Memory Study (WHIMS), die bisher [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Etwa 80% der Frauen im Klimakterium beschreiben \u2013 in sehr unterschiedlicher Auspr\u00e4gung \u2013 Symptome wie Hitzewellen, Schlafst\u00f6rungen, Depression und kognitive Defizite. Neben bekannten Risiken im Zusammenhang mit einer Hormonersatz-Therapie (\u201ehormone replacement therapy\u201c = HRT; vgl.\u00a0) gibt es widerspr\u00fcchliche Untersuchungsergebnisse zur Entwicklung einer Demenz unter HRT \u00a0. Die Women\u2019s Health Initiative Memory Study (WHIMS), die bisher [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[744,5615,59,888,363,360,364,415,745,5560,362,5614,62,359,4289],"class_list":["post-3198","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-demenz","tag-dydroprogesteron","tag-estrogene","tag-gestagene","tag-hormonersatz-therapie","tag-hormonersatztherapie","tag-hrt","tag-levonorgestrel","tag-m-alzheimer","tag-medroxyprogesteron","tag-menopause","tag-norethisteronacetat","tag-oestrogene","tag-postmenopause","tag-whims-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3198","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=3198"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/3198\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=3198"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=3198"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=3198"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}